The Zacks Analyst Blog Highlights: Hanesbrands, Teva Pharmaceutical, Novartis, Biogen Idec and Actavis

Jan 28, 2014, 09:30 ET from Zacks Investment Research, Inc.

CHICAGO, Jan. 28, 2014 /PRNewswire/ -- announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Hanesbrands Inc. (NYSE: HBI-Free Report), Teva Pharmaceutical Industries Limited (NYSE: TEVA-Free Report), Novartis (NYSE: NVS-Free Report),  Biogen Idec (Nasdaq: BIIB-Free Report) and Actavis (NYSE: ACT-Free Report).


Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Monday's Analyst Blog:

Can Hanesbrands (HBI) Keep the Streak Alive?

Hanesbrands Inc. (NYSE: HBI-Free Report) is set to report fourth-quarter fiscal 2013 results on Jan 29. Last quarter, it posted a positive surprise of 7.8%. Let us see how things are shaping up for this announcement.

Factors to Be Considered This Quarter

Hanesbrands has been reporting decent earnings results for the past few quarters backed by the strategic initiative — Innovate-to-Elevate.

In spite of delivering mixed results in the third quarter, Hanesbrands upped its earnings and sales guidance for fourth-quarter fiscal 2013 on the back of opportunity to expand its margins in the coming quarter due to lower cotton costs and the Innovate-to-Elevate strategy, which focuses on high-margin products.

Hanesbrands raised the earnings per share guidance to a range of $3.75 to $3.85 from $3.50 to $3.65. Management expects the Maidenform acquisition contributed 10 cents to the earnings upside. The company expects operating profits between $580 million and $590 million for the year, higher than the previous range of $550 million to $575 million. Net sales are expected slightly above $4.6 billion compared with $4.55 billion in the year-ago period.

Earnings Whispers?

Our proven model does not conclusively show that Hanesbrands is likely to beat earnings this quarter. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 to surpass earnings estimate. However, that is not the case here due to the following factors:

Zacks ESP: ESP for Hanesbrands is 0.00%.

Zacks Rank #3 (Hold): Hanesbrands' Zacks Rank when combined with a 0.00% ESP makes surprise prediction difficult.

We caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions momentum.

Teva Falls on Negative CHMP Opinion

Teva Pharmaceutical Industries Limited (NYSE: TEVA-Free Report) and Active Biotech announced that their oral multiple sclerosis (MS) candidate, Nerventra, received a negative opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The companies are looking to get the candidate approved for the treatment of relapsing-remitting multiple sclerosis (RRMS).

The CHMP rendered a negative opinion as it believes that the potential risks associated with Nerventra outweigh the benefits based on currently available data. Data found in animal studies - a higher occurrence of cancer after long-term exposure to Nerventra - and chances of an adverse effect on the unborn baby when taken by pregnant women, led to the CHMP opinion. Teva and Active Biotech are planning to request a re-examination of the CHMP opinion. Teva's shares fell 2.45% on the news.

Our Take

We are disappointed with CHMP's opinion on Nerventra. The successful development and launch of Nerventra would help strengthen Teva's multiple sclerosis drug portfolio. Teva already has a multiple sclerosis product in its portfolio – Copaxone.

However, Copaxone could start facing generics this year. Last month, Teva provided guidance for 2014 based on two scenarios related to Copaxone – Copaxone remaining exclusive and Copaxone going generic. The entry of Copaxone generics this year could cut total revenues by about $500 million and earnings by 60 cents.

We note that several oral multiple sclerosis therapies are currently available including Novartis' (NYSE: NVS-Free Report) Gilenya and Biogen Idec's (Nasdaq: BIIB-Free Report) Tecfidera among others. Competition in the oral multiple sclerosis market is intense and Nerventra needs to demonstrate superior efficacy and safety to gain share in this market.

Teva carries a Zacks Rank #5 (Strong Sell). Some better-ranked stocks include Actavis (NYSE: ACT-Free Report) carrying a Zacks Rank #2 (Buy).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on HBI - FREE

Get the full Report on TEVA - FREE

Get the full Report on NVS - FREE

Get the full Report on BIIB - FREE

Get the full Report on ACT - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

SOURCE Zacks Investment Research, Inc.